

## **Miller, Veronica CV Table of Contents**

<b>CURRICULUM VITAE</b>	<b>1</b>
<b>EDUCATION AND TRAINING</b>	<b>1</b>
<b>ACADEMIC APPOINTMENTS</b>	<b>1</b>
<b>AWARDS</b>	<b>2</b>
<b>BOARDS and COUNCILS</b>	<b>2</b>
<b>NEW COURSE DEVELOPMENT</b>	<b>2</b>
<b>PUBLICATIONS</b>	<b>3</b>
Peer-Reviewed Publications	3
Invited Chapters, Commentaries, and Editorials	18
Technical Reports	21
Abstracts (not including abstracts before 2000)	23
Invited Presentations	28
<b>TEACHING AND MENTORING (Berkeley)</b>	<b>31</b>
Teaching	31
Mentoring (Berkeley)	32
<b>SERVICE</b>	<b>33</b>
Committee Assignments	33
Editorial Boards & Peer-Reviewer	35
Conference Leadership (selected)	35
<b>MEMBERSHIPS</b>	<b>35</b>

**CURRICULUM VITAE**  
**Veronica Miller, PhD**  
**October 1, 2024**

**Office Address:**           **Forum for Collaborative Research**  
University of California Berkeley  
School of Public Health  
Washington DC Campus  
1608 Rhode Island Ave., Suite 212  
Washington DC 20036  
Phone: 202-974-6290  
[veronicam@berkeley.edu](mailto:veronicam@berkeley.edu)

**Current Position:**       Professor (Adjunct)  
School of Public Health,  
Division of Infectious Diseases & Vaccinology  
University of California Berkeley

**EDUCATION AND TRAINING**

**Education:**               B.Sc. 1976       University of Manitoba (Microbiology)  
Ph.D. 1985       University of Manitoba (Immunology)  
Advisor: Dr. A.H. Greenberg  
Dissertation: "Murine Tumor Reactive Natural  
Antibodies"

**Post-doctoral training:**   1986-1987       Research Associate with Dr. T.B. Tomasi  
University of New Mexico, Department of Cell  
Biology

1987-1989       Assistant Research Immunologist, UCLA School of  
Medicine, Department of Microbiology and  
Immunology

**ACADEMIC APPOINTMENTS**

2017-present   Professor (Adjunct), **University of California  
Berkeley, School of Public Health**, Division of  
Infectious Diseases & Vaccinology  
2010- 2017     Senior Researcher and Lecturer, **University of  
California Berkeley, School of Public Health**  
2007-2010     Research Professor, **The George Washington  
University School of Public Health and Health**

2001-2007	<b>Services;</b> Department of Epidemiology & Biostatistics; Department of Health Policy Associate Research Professor, <b>The George Washington University School of Public Health and Health Services</b>
1993-2001	Director, Interdisciplinary HIV Research, HIV-Outpatient Clinic (Infektionsambulanz), <b>Zentrum der Inneren Medizin, Klinikum der J.W. Goethe-Universität, Frankfurt</b>
1990-1991	Research Assistant Professor, <b>University of New Mexico, School of Medicine</b> , Department of Pathology

## AWARDS

1981-1985	Manitoba Health Research Council Studentship
1988	Travel Support Award, Fogarty International Center
1996	AIDS-Forschungspreis, Deutsche Gesellschaft für Infektiologie
2024	Distinguished Advocacy Service Award, AASLD

## BOARDS and COUNCILS

2008-2016	Scientific Advisory Board, IDSA/HIMVA Infectious Disease Center for Global Health Policy and Advocacy
2016-2018	Scientific Advisory Board (External): Computational Standards for Regulatory Science, FDA-BAA Award to The George Washington University
2019-2024	NIH Office of AIDS Research Advisory Council (OARAC)
2024-	<b>IDEa State Consortium for Clinical Research - Resource Center (ISCORE-RC)</b> External Advisory Committee
2024-2026	Clinical Research Data Sharing Alliance (CRDSA) Board of Directors

## NEW COURSE DEVELOPMENT

2003	PubH 209.21: Issues in HIV Care and Treatment (GWU)
2006	PubH 209.35: Approaches to HIV Prevention: An Interdisciplinary Overview (GWU)
2012	PH236: US Food and Drug Administration, Drug Development and Public Health (UC Berkeley)
2017	PHW236A (OOMPH): Regulatory Science, Drug Development and Global Health (UC Berkeley)

2022 PH290 Seminar: Diagnostics in Infectious Diseases: Development and Regulatory Challenges (Instructor of Record; co-taught with John Sninsky and Pete J. Dailey)

## PUBLICATIONS

### *Peer-Reviewed Publications*

1. Chow DA, Carlson GA, **Miller V**, Pohajdak B, Greenberg AH. Natural resistance to tumors is a heterogeneous immunological phenomenon: Evidence for non-NK cell mechanisms. Invasion and Metastases 1982; 1:205-219.
2. Greenberg AH, **Miller V**, Pohajdak B, Jablonski T. The in vivo effects of interferon suppression of the NK target structure. In: Herberman RB, ed. NK Cells and Other Natural Effector Cells 1982.
3. **Miller V**, Pohajdak B, Greenberg AH. Murine natural anti-tumor antibody. III. Interferon treatment of a natural killer-resistant lymphoma: Augmentation of natural antibody reactivity and susceptibility to in vivo natural resistance. JNCI 1983; 71:377-384.
4. Greenberg AH, **Miller V**, Jablonski T, Pohajdak B. Suppression of NK mediated natural resistance by interferon treatment of murine lymphomas. J. Immunol 1984; 32:2129-2134.
5. Pohajdak B, Lee KC, Sugawara I, **Miller V**, Wright JA, Greenberg AH. Comparative analysis of NK cell and macrophage recognition of ConA resistant Chinese Hamster Ovary Cells: The role of membrane oligosaccharides. JNCI 1986; 136:2968
6. **Miller V**, Lagarde AE, Longenecker BM, Greenberg AH. A phenyl- $\beta$ -galactoside specific monoclonal antibody reactive with murine and rat NK cells. J Immunol 1986; 136:2968
7. **Miller V**, Scofield VL. Role of sperm in HIV transmission. Proceedings from the CONRAD International Workshop: The Heterosexual Transmission of AIDS 1989. Alexander NJ, Gabelnick HL, Spieler JM, ed. Wiley-Liss.
8. **Miller V**, Chow DA, Greenberg AH. Natural Antibodies. In: Nelson DS, ed. Natural Immunity 1989; Academic Press.
9. Willman CL, Stewart C, **Miller V**, Tomasi TB. Regulation of MHC Class II gene expression in macrophages by hematopoietic colony stimulating factors: Induction by GM-CSF and inhibition by CSF-1. J Exp Med 1989; 170:1559.

10. Davis LE, Hjelle BL, **Miller V**, Palmer DL, Lewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA. Early viral brain invasion of iatrogenic human immunodeficiency virus infection. Neurology 1992.
11. Staszewski S, **Miller V**, Kober A, Colebunders R, Vandercam B, Delescluse J, Clumeck N, Van Wanzele F, De Brabander M, De Créé J, Moeremans M, Andries K, Boucher C, Stoffels P, Janssen PA. Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Antiviral Ther. 1996; 1:42-50.
12. Staszewski S, **Miller V**, Rehmet S, Stark T, De Créé J, De Brabander M, Peeters M, Andries K, Moeremans M, De Raeymaeker M, Pearce G, Van den Broeck R, Verbiest W, Stoffels P. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 1996; 10:1-7.
13. Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhoj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H for **the Lamivudine European HIV Working Group**. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996; Jul 10; 276(2): 111-7.
14. **Miller V**, Staszewski S, Boucher CAB, Phair JP. Clinical Experience with Nonnucleoside Reverse Transcriptase Inhibitors. AIDS 1997; 11(suppl A):S157-S164.
15. Staszewski S, Phillips A, Nisius G, **Miller V**. Virological, immunological and clinical effects of stavudine-containing triple-combination therapies in pretreated HIV-1 positive patients. Antiviral Ther 1997; 2(3): Stavudine in the Management of HIV Infection, 133-135.
16. Muller P, Engelstadter M, Werner A, Braner J, Staszewski S, **Miller V**, Doerr HW, Kurth R, Cichutek K. Increased serum and mRNA levels of RANTES associated with elevated levels of activated CD8+CD38+ T cells in HIV-1 infected individuals. Intervirology 1997; 40:263-270.
17. **Miller V**, Phillips A, Rottmann C, Staszewski S, Pauwels R, Hertogs K, de Béthune M-P, Kemp SD, Bloor S, Harrigan PR, Larder BA. Dual resistance to zidovudine (ZDV) and lamivudine (3TC) in patients treated with ZDV/3TC combination therapy: Association with therapy failure. Journal of Infect. Dis. 1998; 177:1521-32.
18. Hertogs K, de Béthune MP, **Miller V**, Ivens T, Schel P, Van Cauwenberge A, Van den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant HIV-1 isolates of patients treated with antiretroviral drugs. Antimicrob. Agents Chemoth. 1998; 42:269-276.
19. **Miller V**, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune M-P, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA. The M184V mutation in HIV-1 reverse transcriptase

conferring 3TC resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998; 12:705-712.

20. Mocroft A, Vella S, Benfield T, Chiesi A, **Miller V**, Kosmidins J, d'Arminio Monteforte, Yust I, Bruun J, Phillips AN, Lundgren JD for the EUROSDIA study group. Changing patterns of mortality in patients infected with HIV. Lancet 1998; 352:1725-1730.

21. **Miller V**, de Béthune M-P, Kober A, Stürmer M, Hertogs K, Pauwels R, Stoffels P, Staszewski S. Patterns of resistance and cross-resistance to HIV-1 reverse transcriptase inhibitors in patients treated with the non-nucleoside reverse transcriptase inhibitor loviride. Antimicrob. Agents Chemother. 1998; 42:3123-3129.

22. Staszewski S, **Miller V**, Sabin C, Berger A, Hill AM, Phillips AN. Rebound of HIV-1 viral load after suppression to very low level [Research Letter] AIDS 1998; 12:2360.

23. Staszewski S, **Miller V**, Sabin C, Carlebach A, Berger A-M, Weidmann E, Helm EB, Hill A, Phillips A. Virological response to protease inhibitor therapy in an HIV clinical cohort. AIDS 1999; 13:367-373.

24. Staszewski S, **Miller V**, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidmann E, Hill A, Phillips A. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999; 13:951-956.

25. **Miller V**, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren J. Relations among CD4 count nadir, antiretroviral therapy and HIV-1 disease progression: results from the EuroSIDA study. Annals of Internal Medicine 1999; 130:570-577.

26. **Miller V**, Staszewski S, Nisius G, Cozzi Lepri A, Sabin C, Phillips AN. Risk of new AIDS diseases in patients on triple therapy. Research letter, Lancet 1999; 353:463.

27. **Miller V**, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Cozzi Lepri A, Phillips AN. CD4 lymphocyte count as a predictor of the duration of HAART-induced suppression of HIV-1 virus load. J Infect Dis. 1999; 180:530-533.

28. Hertogs K, Van Houtte M, Larder B, **Miller V**. Testing for HIV-1 drug resistance: New developments and clinical implications. Recent Res. Devel. Antimicrob. Agent & Chemother. 1999; 3:83-104.

29. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, **Miller V**, Stürmer M, Staszewski S, Ren J, Stammers DK, Stuart DI, Pauwels R. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multi-nucleoside analog resistance. Antimicrob. Agents Chemother. 1999; 43(8):1961-7.

30. Chiesi A, Mocroft A, Dally LG, **Miller V**, Katlama C, Ledergerber B, Pedersen C, Phillips AN, Arcieri R, and Lundgren JD, for the EuroSIDA Study Group. Regional survival differences across Europe in HIV positive people: The EuroSIDA Study. AIDS 1999; 13:2281-2288.
31. **Miller V**, Ait-Khaled A, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M. HIV-1 reverse transcriptase (RT) genotype and viral sensitivity to RT inhibitors during abacavir monotherapy and after switch to zidovudine, lamivudine and abacavir HAART. AIDS 2000; 14(2):163-171.
32. Holtkamp N, Otteken A, Findhammer S, **Miller V**, Kurth R, Werner A. Unexpected co-receptor usage of primary HIV-1 isolates from viremic patients under highly active antiretroviral therapy (HAART). J Infect Dis 2000; 181:513-521.
33. Hertogs K, Bloor S, De Vroey V, Van den Eynde C, Dehertog P, Cauwenberge AV, Stürmer M, Alcorn T, Wegner S, Van Houtte M, **Miller V**, Larder BA. A novel human immunodeficiency virus type 1 (HIV-1) reverse transcriptase mutational pattern confers phenotypic 3TC resistance in the absence of mutation 184V. Antimicrob. Agents Chemother. 2000; 44(3):568-573.
34. Cozzi Lepri A, Sabin C, Staszewski S, Hertogs K, Müller A, Rabenau H, Phillips AN, **Miller V**. Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis. 2000; 181:1143-1147.
35. Rizzardì GP, De Boer RJ, Hoover S, Tambussi G, Bart P-A, Chapuis A, Halkic N, Corpataux J-M, **Miller V**, Staszewski S, Notermans DW, Perrin L, Fox CH, Lange JMA, Lazzarin A, and Pantaleo G. Estimates of length of treatment required to suppress plasma viremia below 50 copies/ml in HIV-1-infected adults. J Clin Invest 2000; 105(6):777-782.
36. Hertogs K, Bloor S, Kemp S, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, **Miller V**, Larder BA. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance. A survey of over 6000 samples. AIDS 2000; 14:1203-10.
37. **Miller V**, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, Bloor S, Klauke S, Rabenau H, Phillips AN and Staszewski S. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV Cohort. Antiviral Ther. 2000; 5:49-55.
38. DeGrutolla V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Jeffrey M, Patick A, **Miller V**, Pedneault L, Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther. 2000; 5:41-48.

39. **Miller V**, Sabin C, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S. The impact of PI-containing HAART on progression of HIV disease and its relationship to CD4 and viral load. AIDS 2000; 14:2129-2136.
40. **Miller V**, Sabin C, Hertogs K, Larder B, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14(18):2857-2867.
41. Mocroft A, **Miller V**, Chiesi A, Blaxhult A, Katlama C, Clotet B, Barton S, Lundgren JD. Virological failure among patients on HAART from across Europe: Results from the EuroSIDA study. Antiviral Ther. 2000; 5:107-112.
42. Youle M, Holtzer C, Simpson K, de Clerq K, **Miller V**. HIV-1 drug resistance testing: health outcomes issues. Antiviral Ther. 2000; 5:113-115.
43. Staszewski S, Haberl A, Carlebach A, Rottmann C, **Miller V**, Gute P. A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users. HIV Medicine 2000; 1:162-163.
44. Gröschel B, **Miller V**, Doerr HW, Cinatl Jr. C. Activity of cellular thymidine kinase 1 in PBMCs of HIV-1 infected patients: novel therapy marker. Infection 2000; 28:209-213.
45. **EuroGuidelines Group**: Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing in treatment management: Recommendations for the European setting. AIDS 2001; 15(3):309-320.
46. Cozzi Lepri A, **Miller V**, Phillips AN, Rabenau H, Sabin CA, Staszewski S. The virological response to HAART over the first 24 weeks of therapy according to the pre-therapy viral load and the week 4-8 viral load. AIDS 2001; (15):47-54.
47. **Miller V**. Structured Treatment Interruptions (STI) in Antiretroviral Management of HIV-1. Current Opinion in Infectious Diseases 2001; 14:29-37.
48. **Miller V**. Resistance to HIV-1 Protease Inhibitors. J Acquir Immune Defic Syndr. 2001;26 Suppl 1:S34-50.
49. Mocroft A, Phillips AN, **Miller V**, Gatell J, van Lunzen J, Parkin JM, Francioli P, Roegge B, Lazzarin A, Lundgren JD on behalf of the EuroSIDA Study Group. The use of and response to second-line protease inhibitor (PI) regimens: Results from the EuroSIDA Study. AIDS 2001;15(2):201-209.
50. Vandamme A-M, Houyez F, Bânhegyi D, Clotet B, De Schrijver G, De Smet KAL, Hall WW, Harrigan R, Hellmann N, Hertogs K, Holtzer C, Larder B, Pillay D, Race E, Schmit JC, Schuurman

- R, Shulse E, Sönnnerborg A, **Miller V**. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antiviral Ther. 2001; 6:21-40.
51. Kirk O, Mocroft A, Pradier C, Bruun JN, Hemmer R, Clotet B, **Miller V**, Viard J-P, Phillips AN, Lundgren JD, and the EuroSIDA Study Group. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. AIDS 2001; 15(8):999-1008.
52. Harrigan PR, Montaner JSG, Wegner SA, Verbiest W, **Miller V**, Wood R, Larder BA. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15(13):1671-1677.
53. Phillips A, **Miller V**, Sabin C, Cozzi Lepri A, Klauke S, Bickel M, Doerr HW, Hill A, Staszewski S. Durability of viral suppression after initial decline in HIV-1 viral load to <50 copies/ml with highly active antiretroviral therapy. AIDS 2001; 15:2379-2384.
54. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, **Miller V**, Gatell JM, Katlama C, Lazzarin A, Skinhoj P, Barton SE, for the EuroSIDA study Group. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active Antiviral Ther. Blood 2001; 98:3406-3412.
55. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, **Miller V**, Vernazza P, Lundgren J, Ledergerber B, on behalf of the Swiss HIV Cohort Study, the Frankfurt HIV Clinic Cohort, and the EuroSIDA Study Group. Initiation of antiretroviral therapy: HIV-1 viral load response according to the baseline CD4 lymphocyte count and viral load. JAMA 2001; 286:2560-2567.
56. **Miller V**, Larder B. Mutational patterns in the HIV genome and cross resistance following nucleoside and nucleotide analogue drug exposure. Antiviral Ther. 2001; 6(Suppl 3): 25-44.
57. **Miller V**, Mocroft A, Clotet B, Ledergerber B, Kirk O, D'Arminio Monforte A, Lundgren J for the EuroSIDA Study Group. Association of viral load, CD4 cell count and treatment with clinical progression in HIV patients with very low CD4 cell counts: The EuroSIDA study. J Infect. Dis. 2002; 186:189-97.
58. **Miller V**, Stark T, Loelliger AE, Lange JMA. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Medicine 2002; 3:135-145.
59. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, **Miller V**, Francioli P, Furrer H, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Hirschel B, Phillips AN, Telenti A, Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16:1967-1968.
60. Cozzi-Lepri A, Phillips AN, **Miller V**, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgren JD. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antiviral Ther. 2003; 8:127-136.

61. Reddy YS, Kashuba A, Gerber J, **Miller V**. Importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. *AIDS Research and Human Retroviruses* 2003; 19:167-176.
62. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, **Miller V** on behalf of the Roundtable Participants. Protein binding in antiretroviral therapies. *AIDS Research and Human Retroviruses* 2003; 19:825-835.
63. Bisson G, Gross R, Evans S, Graham D, Lundgren J, Murray J, Arlett P, Pizzuti D, Primohamed M, Kerft-Jais C, Szarfman A, Justice A, Munk B, Carr A, **Miller V**, Weller I, Walker A. Monitoring of long-term toxicities of HIV treatments: an international perspective. *AIDS* 2003; 17:2407-2417.
64. Brun-Vezinet F, Costagliola D, Ait Khaled M, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, **Miller V**, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V. Clinically validated genotype analysis: guiding principles and statistical concerns. *Antiviral Ther.* 2004; 9:465-478.
65. Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bachelier L, Banhegyi D, Boucher C, Brun-Vezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gaddi G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, **Miller V**, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno DF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. *Antiviral Ther.* 2004; 9:829-848.
66. Struble K, Murray J, Cheng B, Gegeny T, **Miller V**, Gulick R. Antiretroviral therapies for treatment-experienced patients: Current status and research challenges. *AIDS* 2005; 19:747-756.
67. Bickel M, Rickerts V, Stephan C, Jacobi V, Rottmann C, Dauer B, Carlebach A, Thalhammer A, **Miller V**, Staszewski S. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1 infected patients with undetectable plasma viral load. *HIV Medicine* 2005; 6: 179-184.
68. Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, **Miller V**, Respass R, Stevens W. HIV-1 viral load assays for resource-limited settings. *PLOS Medicine* 2006; 3:e417
69. Shafer RW, Rhee S-Y, Pillay D, **Miller V**, Sandstrom P, Schapiro J, Kuritzkes DR, Bennett D. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. *AIDS* 2007; 21:215-223.

70. **Miller V.** Buprenorphine and HIV primary care: Report of a Forum for Collaborative HIV Research Workshop. CID 2006; 43:S253-S257.
71. Lederman MM, **Miller V**, Weller I, Deeks S. A new approach for 'deep' salvage trials in advanced HIV infection. AIDS 2007; 21:1503-1506.
72. Cozzi-Lepri A on behalf of the **Standardization and Clinical Relevance of HIV Drug Resistance Testing Working Group**. Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med 2008; 9:27-40.
73. Assoumou L, Brun-Vezinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, DeGruttola V, **Miller, V**, Costagliola D, on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing Working Group. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 2008; 198:470-480.
74. Bartlett JG, Branson BM, Fenton K, Hauschild BC, **Miller V**, Mayer K. Opt-out testing for HIV: A progress report. JAMA 2008; 300:945-951
75. Chan-Tack KM, Struble KA, Morgensztejn N, Murray JS, Gulick R, Cheng B, Weller I, **Miller V.** HIV clinical trial design for antiretroviral development: moving forward. AIDS 2008; 22(18): 2419-2427.10.1097/QAD.0b013e32831692e6
76. Cheng B, Landay A, **Miller V.** Research needs and challenges in the development of HIV diagnostic and treatment monitoring tests for use in resource-limited settings. Current Opinion in HIV AIDS 2008; 3:495-503.
77. **Miller V.** The Forum for Collaborative HIV Research – a model for an integrated and inclusive approach to clinical research and drug development. Clinical Pharmacology & Therapeutics 2009; 86:332-335
78. Assoumou L, Cozzi-Lepri A, Brun-Vezinet F, DeGruttola V, Kuritzkes D, Phillips A, Zolopa A, **Miller V**, Flandre P, Costagliola D on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing project of the Forum for Collaborative HIV Research. Initiatives for developing and comparing genotype interpretation systems: development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. AIDS 2010; 24:365-371
79. Assoumou L, Houssaini A, Costagliola D, Flandre P on behalf of the **Standardization and Clinical Relevance of HIV Drug Resistance Testing Project** of the Forum for Collaborative HIV Research. Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. Journal of

Antimicrob Chemother. 2010; 65:752-760.

80. DeGruttola V, Smith DM, Little SJ, **Miller V**. Developing and evaluating comprehensive HIV control strategies: Issues and Challenges. CID 2010; 50(Suppl 3) S102-S107.

81. Kwong A, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukulj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky J-M, Petropoulos C, Picchio G, Raltston R, Reeves JD, Schooley RT, Seiwert S, Standing D, Stuyver L, Sullivan J, **Miller V**. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: Recommendations from the HCV DRAG. Gastroenterology 2011; 140:755-760

82. Bakare N, Edwards IR, Stergachis A, Pal S, Holmes CB, Lindquist M, Duncombe C, Dodoo A, Novendstern J, Nwokike J, Kuchenbecker R, Aberg JA, **Miller V**, Strobos J. "Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities." PLoS Med 2011; 8(7): e1001054.10.1371/journal.pmed.1001054

83. Hauschild B, Weddle A, Lubinski C, Tegelvik JK, **Miller V**, Saag M. HIV clinic capacity and medical workforce challenges: Results of a survey of Ryan White Part C-funded programs. Annals of the Forum for Collaborative HIV Research 2011; 13

84. Triant VA, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, **Miller V**, Strobos J. Adverse outcome analysis of observational data: Assessing cardiovascular risk in HIV disease. CID 2012; 54:408-13.

85. Mani N, Murray J, Gulick RM, Josephson F, **Miller V**, Miele P, Strobos J, Struble K. Novel clinical trial designs for the development of new antiretroviral agents. AIDS 2012; 26:899-907.

86. Wedemeyer H, Jensen DM, Dogofsky E, Mani N, Pawlotsky JM, **Miller V**. Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. Hepatology 2012; 56:2398-2403.

87. **Miller V**, Nwokike J, Stergachis A. Pharmacovigilance and global HIV/AIDS. Curr Opin HIV AIDS 2012; 7:299-304.

88. Houssaini A, Assoumou L, **Miller V**, Calvez V, Marcelin AG, Flandre P. Scoring methods for building phenotypic scores: an application to didanosine resistance in a large derivation set. PLoS One 2013; 8(3): e59014

89. Lontok E, Mani N, Harrington PR, **Miller V**. Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy. Clin Infect Dis. 2013; 56(10): 1466-1470.10.1093/cid/cit025

90. Panneer N, Lontok E, Branson BM, Teo C-G, Dan C, Parker M, Stekler JD, DeMaria A, **Miller V**. HIV and HCV Testing: HIV and hepatitis C virus infection in the United States: Whom and how to test. Clin Infect Dis. 2014; 59(6): 875-882.
91. Hutchison C, Kwong A, Ray S, Struble K, Swan T, **Miller V**. Accelerating drug development through collaboration: The hepatitis C drug development advisory group (HCV DrAG). Clin Pharmacology & Therapeutics 2014; 96(2):153-55.
92. **Miller V**, Grant RM. Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition. Clin Pharmacol Ther. 2014; 96(2): 153-155.10.1038/clpt.2014.114.
93. Lontok, E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, **Miller V**. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 2015; 62(5): 1623-1632.10.1002/hep.27934
94. Sanyal AJ, **Miller V**. Regulatory science and drug approval for alcoholic and non-alcoholic steatohepatitis. Gastroenterology 2016; 150(8) 1723-27: 10.1053/j.gastro.2016.02.044. Epub 2016 Feb 26.
95. McIntosh M, Hauschild B, **Miller V**. Human cytomegalovirus and transplantation: drug development and regulatory issues. Journal of Virus Eradication 2016; 2:143-248
96. Winston A, Stohr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabie A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L, Neat Agence Nationale de Recherche sur le SIDA **143 Study Group**. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. HIV Med 2016; 17(6): 471-478.10.1111/hiv.12344.
97. Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F, **Neat Anrs Study Group**. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. J Antimicrob Chemother. 2016; 71(4): 1056-1062.10.1093/jac/dkv427.
98. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, **Miller V**, Griffiths PD. Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis. 2017; 64(1): 87-91.10.1093/cid/ciw668.
99. Liu J, Goicochea P, Block T, Brosgart CL, Donaldson EF, Lenz E, Lim SG, Marins EG, Mishra P, Peters MG, **Miller V**. Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders' consultation. Journal of Virus Eradication 2017; 3:1-6.

100. Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe AYM, **Miller V**, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Sequencing of hepatitis C virus for detection of resistance to direct-acting Antiviral Ther.: A systematic review. Hepatology. 2017; 1(5): 379-390.10.1002/hep4.1050.
101. Ivanova Reipold E, Easterbrook P, Trianni A, Panneer N, Krakower D, Ongarello S, Roberts T, **Miller V**, Denkinger C. Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile. BMC Infect Dis. 2017; 17(Suppl 1): 707.10.1186/s12879-017-2770-5.
102. Patel YA, Imperial JC, Muir AJ, Anstee QM, DeBrotta D, Dimick-Santos L, Filozof C, Mehta R, Sanyal AJ, Schabel E, Neuschwander-Tetri BA, **Miller V**, Liver Forum's Data Standardization Working Group. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations from the Liver Forum. Gastroenterology 2017; 153(3): 621-625 e627.10.1053/j.gastro.2017.07.024.
103. Tucke JD, Meyers K, Best J, Kaplan K, Pendse R, Fenton KA, Andrieux-Meyer I, Figueroa C, Goicochea P, Gore C, Ishizaki A, Khwairakpam G, **Miller V**, Mozalevskis A, Ninburg M, Ocama P, Peeling R, Walsh N, Colombo MG, Easterbrook P. The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing. BMC Infect Dis. 2017; 17(Suppl 1): 701.10.1186/s12879-017-2771-4.
104. Lazarus JV, Block T, Brechot C, Kramvis A, **Miller V**, Ninburg M, Penicaud C, Protzer U, Razavi H, Thomas LA, Wallace J, Cowie BC. The hepatitis B epidemic and the urgent need for cure preparedness. Nat Rev Gastroenterol Hepatol 2018; 15(9): 517-518.10.1038/s41575-018-0041-6.
105. Natori Y, Alghamdi A, Tazari M, **Miller V**, Husain S, Komatsu T, Griffiths P, Ljungman P, Orchanian-Cheff A, Kumar D, Humar A. Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018; 66(4): 617-631.10.1093/cid/cix793.
106. Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, **Miller V**, Sanyal AJ, Liver Forum Case Definitions Working Group. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018; 67(5): 2001-2012.10.1002/hep.29607.
107. Dube K, Dee L, Evans D, Sylla L, Taylor J, Brown B, **Miller V**, Corneli A, Skinner A, Greene S B, Tucker JD, Rennie S. Perceptions of Equipoise, Risk-Benefit Ratios, and "Otherwise Healthy Volunteers" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics 2018; 13(1): 3-17.10.1177/1556264617734061.

108. Anderson RT, Lim SG, Mishra P, Josephson F, Donaldson E, Given B, **Miller V**. Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus. Gastroenterology 2019; 156(3): 529-533 e524.10.1053/j.gastro.2018.11.062

109. Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, Lischka P, Josephson F, Douglas CM, Umeh O, **Miller V**, Ljungman P, Resistant Definitions Working Group of the CMV Forum. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2019; 68(8): 1420-1426.10.1093/cid/ciy696

110. Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, **Miller V**, Liver Forum Case Definitions Working Group. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology 2019; 70(5): 1841-1855.10.1002/hep.30672

111. Vos MB, Dimick-Santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Sztitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, **Miller V**, Lavine JE, Liver Forum Pediatric Working Group. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 157(6): 1448-1456 e1441.10.1053/j.gastro.2019.08.048

112. Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R, Ice-Hbv working groups, **Ice-Hbv Stakeholders Group Chairs**, Ice-Hbv Senior Advisors, Zoulim F. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 2019; 4(7): 545-558.10.1016/S2468-1253(19)30119-0

113. Julg B, Ananworanich DJ, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dube K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, **Miller V**, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Sogaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV 2019; 6(4): e259-e268.10.1016/S2352-3018(19)30052-9

114. Fontana RJ, Avigan MI, Janssen HLA, Regev A, Mishra P, Gaggar A, Brown N, Wat C, Mendez P, Anderson RT, Given B, **Miller V**, Beumont M. Liver safety assessment in clinical trials of new agents for chronic hepatitis B. J Viral Hepat. 2020; 27(2): 96-109.10.1111/jvh.13223

115. Nouredin M, Chan JL, Barradas K, Dimick-Santos L, Schabel E, Omokaro SO, Anania FA, Myers RP, **Miller V**, Sanyal AJ, Chalasani N. Attribution of Nonalcoholic Steatohepatitis as an

Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. Gastroenterology 2020; 159(2): 422-427 e421.10.1053/j.gastro.2020.04.039

116. Glass O, Filozof C, Nouredin M, Berner-Hansen M, Schabel E, Omokaro SO, Schattenberg JM, Barradas K, **Miller V**, Francque S, Abdelmalek MF, Liver Forum Standard of Care Working Group. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. J Hepatol 2020; 73(3): 680-693.10.1016/j.jhep.2020.04.030

117. Lazarus JV, Colombo M, Cortez-Pinto H, Huang TT, **Miller V**, Ninburg M, Schattenberg JM, Seim L, Wong VWS, Zelber-Sagi S. NAFLD - sounding the alarm on a silent epidemic. Nat Rev Gastroenterol Hepatol 2020; 17(7): 377-379.10.1038/s41575-020-0315-7

118. Cornberg M, Lok AS, Terrault NA, Zoulim F, Easl-Aasld Hbv Treatment Endpoints **Conference Faculty**. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol 2020; 72(3): 539-557.10.1016/j.jhep.2019.11.003

119. Fidler S, Stohr W, Pace M, Dorrell L, Lever A, Pett S, Kinloch-de Loes S, Fox J, Clarke A, Nelson M, Thornhill J, Khan M, Fun A, Bandara M, Kelly D, Kopycinski J, Hanke T, Yang H, Bennett R, Johnson M, Howell B, Barnard R, Wu G, Kaye S, Wills M, Babiker A, Frater J, **River trial study group**. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet 2020; 395(10227): 888-898.10.1016/S0140-6736(19)32990-3

120. Mbichila T, Kumwenda G, Yola N, Karim QA, Tchelidze T, Lau J, Buchholz S, Lehnert R, Molina JM, Mayer K, **Miller V**. Commentary title: COVID-19 research, Africa, and global health. J Virus Erad. 2021; 7(1): 100030.10.1016/j.jve.2021.100030

121. Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, Donaldson E, Westman G, Buchholz S, **Miller V**, Hansen BE. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021; 19(3): 463-472.10.1016/j.cgh.2020.05.041

122. Clearfield E, **Miller V**, Nadglowski J, Barradas K, Al Naber J, Sanyal AJ, Neuschwander-Tetri BA, Messner DA, coreNASH Panel: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. Hepatol Commun. 2021; 5(5): 774-785.10.1002/hep4.1678.

123. Jahanshahi M, Gregg K, Davis G, Ndu A, **Miller V**, Vockley J, Ollivier C, Franolic T, Sakai S. The Use of External Controls in FDA Regulatory Decision Making. Ther Innov Regul Sci. 2021; 55(5): 1019-1035.10.1007/s43441-021-00302-y.

124. Donnell D, Zewdie K, Ratna N, **Miller V**, Saunders JM, Gill ON, Delpech V, Mohammed H. Association between rectal gonorrhoea and HIV incidence in men who have sex with men: a meta-analysis. Sex Transm Infect. 2022; 98(7): 492-496.10.1136/sextrans-2021-055254.
125. Gehring AJ, Mendez P, Richter K, Ertl H, Donaldson EF, Mishra P, Maini M, Boonstra A, Lauer G, de Creus A, Whitaker K, Martinez SF, Weber J, Gainor E, **Miller V**. Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection. J Hepatol 2022; 10.1016/j.jhep.2022.02.020.
126. Imlay H, Baum P, Brennan DC, Hanson KE, Hodges MR, Hodowanec AC, Komatsu TE, Ljungman P, **Miller V**, Natori Y, Nickleit V, O'Rear J, Pikis A, Randhawa PS, Sawinski D, Singh H K, Westman G, Limaye AP. Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clin Inf Dis. 2022; 75(7): 1210-1216.10.1093/cid/ciac071.
127. Lau J, Murdock N, Murray J, Justman J, Parkin N, **Miller V**. A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications. J Virus Erad. 2022; 8(3): 100085.10.1016/j.jve.2022.100085.
128. Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Duerr A, Glidden DV, Hughes JP, Murray J, Robertson MN, Zinserling J, Lau J, **Miller V**. Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. Clin Pharmacol Ther. 2022; 10.1002/cpt.2830.
129. Zoulim F, Zlotnick A, Buchholz S, Donaldson E, Fry J, Gaggar A, Hu J, Kann M, Lenz O, Lin K, Mani N, Nassal M, Delaney W, Wang S, Westman G, **Miller V**, Janssen HLA. Nomenclature of HBV core protein-targeting antivirals. Nat Rev Gastroenterol Hepatol 2022; 19(12): 748-750.10.1038/s41575-022-00700-z.
130. Kidwell KM, Roychoudhury S, Wendelberger B, Scott J, Moroz T, Yin S, Majumder M, Zhong J, Huml RA, **Miller V**. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Orphanet J Rare Dis. 2022; 17(1): 186.10.1186/s13023-022-02342-5.
131. Kramvis A, Chang K-M, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van Bommel F, Andrisani O, Beumont-Mauviel M, Block TM, Chan HLY, Cloherty GL, Delaney WE, Geretti AM, Gehring A, Jackson K, Lenz O, Maini MK, **Miller V**, Protzer U, Yang JC, Yuen M-F, Zoulim F, Revill PA. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol 2022; 19(11): 727-745.10.1038/s41575-022-00649-z.
132. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagstrom H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, **Miller V**, Newsome PN, Ninburg M, Ocamo P, Ratziu V, Rinella M, Romero D,

Romero-Gomez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S, NALFD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022; 19(1): 60-78.10.1038/s41575-021-00523-4.

133. Mofokeng N, Maponga TG, van Schalkwyk M, Hugo S, Morobadi MD, Vawda S, Badenhorst L, van Vuuren C, van Rensburg C, Preiser W, Taljaard J, Wang S, **Miller V**, Wu D, Tucker JD, Seeley J, Goedhals D, Matthews PC. Barriers that prevent adults living with HBV infection from participating in clinical research: experience from South Africa. J Virus Erad. 2023; 9(1): 100317.10.1016/j.jve.2023.100317.

134. Pais R, Cariou B, Noureddin M, Francque S, Schattenberg JM, Abdelmalek MF, Lalazar G, Varma S, Dietrich J, **Miller V**, Sanyal A, Ratziu V. A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials. J Hepatol 2023; 10.1016/j.jhep.2023.03.014.

135. Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani S, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Hagstrom H, Huang, T, Wajcman DI, Kautz A, Kopka C, Krag A, **Miller V**, Newsome P, Rinella ME, Romero D, Sarin S, Silva M, Spearman CW, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg J, Wong V, Younossi Z. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol 2023; 10.1016/j.jhep.2023.04.035.

136. Gandhi M, Nachega J, **Miller V**, Wilkin T. Benefits and limitations of single-arm study for LA-ART among HIV-infected viremic patients. JIAS 2023; 10.1002/jia2.26093.

137. Pruden HJ, Tatoud R, Janes H, Wallace S, **Miller V**, Bekker L-G, Donnell D. Perspectives on design approaches for HIV prevention efficacy trials. AIDS Research Human Retroviruses 2023; 10.1089/aid.2022.0150.

138. Wedermeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor J, Kessler HH, Lenz O, Luetgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, **Miller V**, Terrault N, Lampertico P. HDV RNA assays: performance characteristics, clinical utility, and challenges. Hepatology 2023; 10.1097/HEP.0000000000000584.

139. Peters MG, Yuen MF, Terrault N, Fry J, Lampertico P, Gane E, Hwang C, Stamm LM, Leus M, Maini MK, Mendez P, Lonjon-Domanec I, Berg T, Wang S, Mishra P, Donaldson E, Buchholz S, **Miller V**, Lenz O. Chronic hepatitis B finite treatment: similar and different concerns with new drug classes. Clin Inf Dis. 2023; 10.1093/cid/ciad506.

140. Krag A, Buti M, Lazarus JV, Allen AM, Bowman J, Burra P, Donnini G, Duseja A, El-Sayed M H, Gastaldelli A, Hainsworth B, Karlsen TH, Kessler M, Korenjak M, Mark HE, Mann JP, **Miller V**, Pessoa MG, Pineiro D, Sarin SK, Singh SP, Rinella ME, Willemse J, Younossi ZM, Francque SM.

Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives. J Hepatol 2023; 10.1016/j.jhep.2023.07.029.

141. Palmer M, Kleiner DE, Goodman Z, Brunt E, Avigan M, Regev A, Hayashi P, Lewis J, Mehta R, Harrison S, Siciliano M, McWherter CA, Vuppalanchi R, Behling C, **Miller V**, Chalasani N, Sanyal A. Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum. Aliment Pharmacol Ther. 2024; 10.1111/apt.17762.

142. Zannad F, Sanyal A, Butler J, Ferreira JP, Girerd N, **Miller V**, Pandey A, Parikh CR, Ratziu V, Younossi ZM, Harrison SA. MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. Journal of Internal Medicine 2024; 10.1111/joim.13793.

143. Leus M, Treat M, **Miller V**, Reingold A. Recommendations from the Forum for Collaborative Research's symposium on hepatitis B elimination and universal hepatitis B adult vaccination in the United States. J Virus Erad. 2024; 10.1016/j.jve.2024.100376.

144. Murdock N, Alajaji NE, Schaefer R, Boone CA, Campo RE, Dore GJ, Gandhi M, Gorospe JR, Gulick RM, Hodder SL, Liu J, Rhee MS, Rooney JF, Vannappagari V, Wilkin T, **Miller V**. Long-acting HIV treatments: study design, logistics, and access. Open Forum Infectious Diseases 2024; 10.1093/ofid/ofae337.

145. Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, **Miller V**, Griffiths PD, Kotton CN for the CMV Definitions Working Group. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from Transplant Associated Virus Infections Forum. Clin Inf Dis. 2024; 10.1093/cid/ciae321.

146. Zannad F, Sanyal A, Butler J, **Miller V**, Harrison SA. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nature Medicine 2024; 10.1038/s41591-024-03223-z.

147. Schaefer R, Ayvaz A, Hoffman CR, Yann M, Rooney Z, Leus M, Mitra S, **Miller V** for the Forum for Collaborative Research. Twenty-five years of addressing cutting-edge scientific, policy, and regulatory issues through collaboration: The Forum for Collaborative Research. Clinical and Translational Science 2024; 10.1111/cts.70051.

#### *Invited Chapters, Commentaries, and Editorials*

1. **Miller V**. Richtlinien für die Durchführung klinischer Studien mit antiretroviralen Substanzen. In: Brodt, Helm Kamps eds. AIDS 1995, Steinhäuser Verlag, 1995.

2. Staszewski S. and **Miller V.** Grundlagen und neuere Konzepte der antiretroviralen Therapie. In: L'age-Stehr and Helm, eds. AIDS und die Vorstadien, Springer Verlag, 1996.
3. **Miller V.** Neue Perspektiven in der antiretroviralen Therapie - die Post-Concorde Ära. In Jäger, Ed. AIDS und HIV-Infektionen in Klinik und Praxis, Monographienreihe Band 5, Ecomed, 1996.
4. **Miller V.** Antiretrovirales Therapie-Management bei HIV. In Jäger, Ed. AIDS und HIV-Infektionen in Klinik und Praxis, Monographienreihe Band 5, Ecomed, 1996.
5. **Miller V**, Staszewski S. Zur Problematik der Resistenzentwicklung von HIV-1 unter antiretroviraler Therapie: Eine Übersicht. In HIV-Infektion: Pathogenese, Diagnostik und Therapie. Ed: Ruf, Pohle, Goebel and L'age. Media Bibliothek, 1996, Germany.
6. Staszewski S, **Miller V.** Antiretrovirale Therapie: Wie beginnen und wie fortsetzen? In Brockmeyer NH & Mertins L Ed. HIV-Infekt: Pathogenese, Diagnostik, Therapie. Springer Verlag, Berlin, 1997.
7. **Miller, V.** Laboruntersuchungen bei HIV-Infektion. In: Therapien bei AIDS, 1997; Referat Medizin und Gesundheitspolitik der Deutschen AIDS-Hilfe e.V.
8. Staszewski S, **Miller V**, Helm EB. Grundlagen und Strategien der antiretroviralen Therapie der HIV-1 Infektion – Stand 1997. In: L'age-Stehr and Helm, eds. AIDS und die Vorstadien, Springer Verlag, 1996.
9. **Miller V**, Staszewski S. Grundlagen und klinische Bedeutung der Resistenzentwicklung unter antiretroviraler Therapie. In: L'age-Stehr and Helm, eds. AIDS und die Vorstadien, Springer Verlag, 1998.
10. Link R, **Miller V**, Fatkenheuer G, Manegold C, Harrer T. HIV Infection. Virus resistance: development and prevention. Med Monatsschr Pharm 1999 Mar; 22(3): 86-88.
11. Kessler HA, Cohen CA, Johnson VA, Kuritzkes D, **Miller V.** Update on resistance: addressing the issues in 1999. World Health CME, CME credits sponsored by RUSH. World Health Communications Inc, New York NY; 1999.
12. **Miller V.** HIV Resistenztestung in der Praxis. Theoretische Aspekte und klinische Relevanz. Kliniker 1999; 11/28:320-324.
13. Exner-Freisfeld H, **Miller V**, Stamm S, Staszewski S, Stille W. Resistenzuntersuchungen im Therapiemanagement der HIV-Krankheit. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz, Springer Verlag 1999;42:432-435.

14. Lange JMA, Balzarini J, Harrer T, Kleim J-P, Loveday C, **Miller V**, Raffi F, Smith KY, Spira B, Wainberg M. The M184V Mutation in HIV therapy: Impact on clinical care. World Health Communications Inc, eds. New York NY; 2000.
15. **Miller V**. European guidelines on resistance testing: why are they needed? Guest Editorial for HIV Medicine 2000; 1:129-131.
16. Bickel M, Rickerts V, Klauke S, Gould J, Goldbach J, **Miller V**, Staszewski S. Die PROTRA-Studie: Efavirenz (EFV) und Abacavir (ABC) in Kombination anstelle des Protease-Inhibitors (PI) für Patienten, die mit 2 NRTI und einem PI mit der Viruslast unter der Nachweisgrenze von 50 Kopien/ml sind. In Jäger (Ed). AIDS und HIV-Infektionen in Klinik und Praxis, Monographienreihe Band 8, Moderne Industrie Verlag, 2000.
17. **Miller V**. Evaluating structured treatment interruptions: rationale, experience, potential risks, and benefits. The PRN Notebook 2000; 5:23-27.
18. **Miller V**. Is there a case for continuing therapy despite virological failure? J HIV Therapy 2000; 5:67-71.
19. Kuritzkes DR, Loveday C, **Miller V**, Raffi F, Opravil M, Lange J, Wainberg M, Rozenbaum W. Abacavir Resistance Roundtable Monograph. MediTech Media Ltd, UK; 2000.
20. Markowitz MM, **Miller V**. Letter from Sitges: Selected highlights from the 4<sup>th</sup> International Workshop on HIV Drug Resistance and Treatment Strategies. The PRN Notebook 2000; 5 (3): 26-31.
21. **Miller V**. The prevalence of drug-resistant HIV as revealed by cohort studies. Guest editorial for HIV & AIDS Current Trends 2000; 6 (4):1-3.
22. Hogg RS, Havlir D, **Miller V**, Montaner JSG. To stop or not to stop: That is the question, but what is the answer? AIDS 2002; 16:1-3.
23. **Miller V**. Treatment interruptions in the salvage setting: What have we learned? RITA! 2003; 9:17-19.
24. **Miller V**. HIV-1 co-infection and superinfection: generation of viral diversity. Guest Editorial. HIV & AIDS Current Trends 2004; 10:1.
25. **Miller V**. Bangkok 2004: Progress in spite of protest? The PRN Notebook 2004; 9:33-36.
26. **Miller V**. Sifting through the maze of viral and host diversity and clinical progression. Commentary in Int. J. Epi. 2005; 34:584-585.

27. **Miller V.** Defining clinically relevant HIV drug resistance – from drug development to clinical reality. AIDS 2006; 20:929-931.
28. Khalsa J, Vocci F, Altice F, Fiellin D, **Miller V.** Buprenorphine and HIV primary care: New opportunities for integrated treatment – Introduction. CID 2006; 43:S169-S172.
29. Hoxie JA, **Miller V.**, Walker B. Tuberculosis and HIV coinfection: genesis of the supplement and sponsors' contribution. J Infect Dis. 2007; 196 Suppl 1:S4.
30. **Miller V.** Afterword: The HIV/AIDS Epidemic. Chapter for *Essentials of Public Health Biology; A Guide to the Study of Pathophysiology*, by Battle, CU. October 15, 2008; Jones and Bartlett, Sudbury MA.
31. **Miller V.**, Horberg M. Editorial Comment. Getting to normal: are we there yet? AIDS 2013; 27(6):1027-28.
32. **Miller V.**, Hodder S. Editorial Comment. Beneficial impact of antiretroviral therapy on non-AIDS mortality. AIDS 2014; 28(2):273–274
33. **Miller V.** Bridging the Gap Between Biomedical Innovation and Access to Treatments to Fight Infectious Disease. Chapter 11 in *Global Management of Infectious Disease after Ebola*. Eds: S Halabi, L O Gostin, J S Crowley. Oxford, 2016

#### *Technical Reports*

1. Jefferys R, **Miller V.** Structured Treatment Interruptions Workshop Summary. HIV Forum Annals 2002; Vol. 1
2. Palen J, **Miller V.** Linking HIV Testing, Prevention and Care. HIV Forum Annals 2001; Vol 4.
3. Mascolini M, Cheng B, **Miller V.** Transfer of HIV Diagnostic and Monitoring Technologies to Resource-Poor Settings. HIV Forum Annals 2002; Vol 5.
4. Jefferys R, **Miller V.** STI Roundtable Discussion: Moving the Agenda Forward. HIV Forum Annals 2003; Vol 6.
5. Mascolini M, **Miller V.** What Defines HIV Lipodystrophy? HIV Forum Annals 2002; Vol 5.
6. **Miller V.** Sex and Gender Issues in HIV Disease. HIV Forum Annals 2002; Vol 5.
7. **Miller V.** Quality of HIV Care – Closing the Gap. HIV Forum Annals 2003; Vol 6.

8. Mascolini M, **Miller V.** Cardiovascular Risk in HIV Infection and Treatment. HIV Forum Annals 2003; Vol 6.
9. Cheng B, Moody K, **Miller V.** QA/QC of CD4 and Viral Load Assays in the Resource Limited Setting. HIV Forum Annals 2003; Vol 6.
10. Warden J, Hunter C, **Miller V.** Buprenorphine and primary HIV care. HIV Forum Annals 2005; Vol 7.
11. Snyder S, Cheng B, **Miller V.** Regulatory Considerations for the Treatment of Lipodystrophy. A roundtable discussion amongst clinical investigators and representatives from industry, advocacy and government. HIV Forum Annals 2004; Vol 7.
12. Levi J, **Miller V.** Developing an HIV health services research agenda. HIV Forum Annals 2005; Vol 7.
13. Hunter C, **Miller V.** Racial-Ethnic Minority Issues in HIV/AIDS. Report of a Forum for Collaborative HIV Research Workshop. HIV Forum Annals 2006; Vol 8
14. Cheng B, **Miller V.** Pediatric HIV Diagnosis and Laboratory Monitoring. Report of a Forum for Collaborative HIV Research Working Group Meeting. HIV Forum Annals 2006; Vol 8.
15. Collins C, Lyon M, **Miller V.** A New Era for HIV Prevention? Report of the Forum for Collaborative HIV Research Biomedical Interventions for HIV Prevention Working group. HIV Forum Annals 2006; Vol 8.
16. Fry J, Bogulavsky Grossman J, **Miller V.** Collaborative Approaches to HIV Drug Development: Planning for Long-Term Monitoring of Safety in CCR5 Antagonist Development. HIV Forum Annals 2007; Vol 9.
17. Zechman E, Cheng B, **Miller V.** Re-Thinking the Approach to Expanded Access Programs. HIV Forum Annals 2007; Vol 9
18. Bakare N, **Miller V.** HIV-TB Co-Infection: Meeting the Challenge. HIV Forum Annals 2007; Vol 9.
19. Bakare N, **Miller V.** Meeting the Demand for Male Circumcision. HIV Forum Annals 2009; Vol 10.
20. Kim S, Mischra S, **Miller V.** Evaluation of Impact of Adult Male Circumcision Programs on HIV Incidence and Prevalence: Current Research, Gaps in Knowledge and Recommendations for Additional Research. HIV Forum Annals 2009; 11(1): 1-13.

21. Hauschild BC, Onaga L. Metrics and Evaluations Measures for Monitoring the Implementation of Routine HIV Testing. HIV Forum Annals 2010; 11(2): 1-15.
22. Hauschild BC, **Miller V**, Strobos S. Municipal scale-up of HIV testing in the United States: Current status, challenges and opportunities from a multi-stakeholder perspective. HIV Forum Annals. 13(4): 1-8.
23. Strobos J, Hauschild BC, **Miller V**. Safety considerations in the prevention of transmission of HIV by Pre-Exposure Prophylaxis (or “PrEP”). HIV Forum Annals 2011; 13(5): 1-11.
24. HCV Phenotype Working Group of the HCV Drug Development Advisory Group. Clinically relevant HCV drug resistance mutations. HIV Forum Annals 2012; 14(2): 1-10.

*Abstracts (not including abstracts before 2000)*

1. Hertogs K, De Vroey V, Van Den Eynde C, Dehertogh P, Vanbloor A, **Miller V**, Alcorn T, Larder B, Cauwenberge S. Common, Rare, and New HIV-1 Resistance Profiles Observed in Routine Clinical Practice: A Survey of over 5,000 Isolates and the Characterization of a Novel 3TC Resistance Mutational Profile Lacking 184V. *7<sup>th</sup> Conference on Retroviruses and Opportunistic Infections 2000; San Francisco, USA Jan 30- Feb 2; Abstract 740.*
2. Ledergerber B, Mocroft A, Reiss P, Furrer HJ, Kirk O, **Miller V**, Pradier C, Uberti-Foppa C, D'Arminio Monforte A, Schneider MM, Lundgren JD. It Is Safe to Discontinue Secondary Prophylaxis for PCP in HIV-Infected Patients Treated with HAART: Results from Eight Prospective European Cohorts. *7<sup>th</sup> Conference on Retroviruses and Opportunistic Infections 2000; San Francisco, USA Jan 30- Feb 2; Abstract LB5.*
3. De Smet K, Celis L, Schmit JC, Fransen K, **Miller V**, Soriano V, Quinn T, Molijn A, Stuyver L. Performance of the INNO-LiPA HIV nucleosides assay for the rapid identification of key mutations correlated with resistance to nucleoside analogue reverse transcriptase inhibitors. In *Programme and Abstracts of the 2<sup>nd</sup> Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance 2000; Frankfurt, Germany 25-27 February; Abstract 54.*
4. **Miller V**, Sabin C, Hertogs K, Martinez-Picado J, D'Aquila R, Larder B, Bloor S, Stürmer M, Rottmann C, Phillips AN, Staszewski S. Antiretroviral treatment interruptions in patients with treatment failure: analysis from the Frankfurt HIV Cohort. In *Programme & Abstracts of the Third International Workshop on Salvage Therapy for HIV Infection; Chicago, USA 12-14 April 2000; Abstract 25. Antiviral Ther.* 2000; 5(Suppl 2):22.
5. Mocroft A, Lundgren JD, Phillips AN, for the EuroSIDA Group. Response to salvage therapy in patients exposed to all three classes of antiretrovirals: the **EuroSIDA** study. In *Programme & Abstracts of the Third International Workshop on Salvage Therapy for HIV Infection; Chicago, USA 12-14 April 2000; Abstract 4. Antiviral Ther.* 2000; 5(Suppl 2):4-5.

6. Miller MD, Margot NA, Hertogs K, Larder B, **Miller V**. Anti-HIV activity profile of tenofovir (PMPA) against a panel of nucleoside-resistant clinical samples. *4<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies; Sitges, Spain 12-16 June 2000*; **Abstract 4**. Antiviral Ther. 2000; 5(suppl 3):4.
7. **Miller V**, Phillips AN, Mocroft A, Loveday C, Hertogs K, Larder B, Stoffels P, Kirk O, Blaxhult A, D'Arminio Monteforte A, Ledergerber B, Colebunders R, Lundgren JD for the EuroSIDA Study Group. Resistance and response to PI treatment in RTId- and PI-experienced patients: The EuroSIDA Cohort Study. *4<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies; Sitges, Spain 12-16 June 2000*; **Abstract 92**. Antiviral Ther. 2000; 5(suppl 3):73.
8. De Smet KAL, Schmit JC, Florence E, **Miller V**, Soriano V, Quinn T, Celis L. Identifying minority quasispecies of resistant HIV in clinical samples. *4<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies; Sitges, Spain 12-16 June 2000*; **Abstract 102**. Antiviral Ther. 2000; 5(suppl 3):80.
9. Phillips AN, Loveday C, **Miller V**, Kirk O, Mocroft A, d'Arminio Monforte A, et al. Factors associated with the presence of resistance used in people with viral load >1000 copies/ml >16 weeks after starting their first protease inhibitor regimen. *4<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies; Sitges, Spain 12-16 June 2000*; **Abstract 121**. Antiviral Ther. 2000; 5(suppl 3):96.
10. Bickel M, Rickerts V, Klauke S, Gould J, **Miller V**, Staszewski S. The PROTRA Study: To evaluate the safety and efficacy of abacavir (ABC) and efavirenz (EFV) when substituted for a PI in HIV-1 infected subjects treated with 2 NRTIs and a PI with plasma HIV-RNA levels below the limit of assay quantification. *XIII International AIDS Conference; Durban, South Africa 9-14 July 2000*; **Abstract TuPeB3210**.
11. Soriano V, Kirk O, Antunes F, Johnson M, d'Arminio Monforte A, Teglbjorg LS, Goebel F-D, Lundgren JD, **for the EuroSIDA Study Group**. The influence of Hepatitis C virus (HCV) on the prognosis of HIV-infected persons: The EuroSIDA Study. *XIII International AIDS Conference; Durban, South Africa 9-14 July 2000*; **Abstract ThOrB655**.
12. Vanhems P, Kirk O, Mocroft A, **for the EuroSIDA Study Group**. Factors associated with starting HAART and pneumocystis carinii pneumonia (PCP) prophylaxis among HIV seroconverters enrolled in the EuroSIDA study. *XIII International AIDS Conference; Durban, South Africa 9-14 July 2000*; **Abstract TuPeC3372**.
13. Bickel M, Rickerts V, Klauke S, Gould J, Goldbach J, **Miller V**, Staszewski S. The PROTRA Study: Switch from PI to abacavir (ABC) and efavirenz (EFV) in HIV-1 infected adults previously treated with 2 NRTIs and a PI with undetectable HIV-RNA levels (vRNA). *40<sup>th</sup> ICAAC; Toronto, Canada 17-20 September 2000*; **Abstract 1531**.

14. Miller MD, Margot NA, Hertogs K, Larder B, **Miller V**. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant HIV samples. *40<sup>th</sup> ICAAC; Toronto, Canada 17-20 September 2000*; **Abstract 2115**.
15. Rottmann C, **Miller V**, Haberl A, Müller A, Rabenau H, Staszewski S. Abacavir (ABC) based triple nucleoside analogues (NRTIs) versus protease inhibitor (PI) containing regimens in antiretroviral naive patients with a CD4 count of less than 100 and/or AIDS. Observational data from the Frankfurt Cohort. *Fifth International Congress on drug therapy in HIV infection; Glasgow, Scotland 22-26 October 2000*; **Abstract P59**. AIDS 2000; 14(Suppl 4):S33.
16. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, **Miller V**, Vernazza P, Lundgren J, and Ledergerber B on behalf of the Swiss HIV Cohort Study, the Frankfurt HIV Cohort and the EuroSIDA Study Group. Viral load changes in response to antiretroviral therapy according to the baseline CD4 lymphocyte count and viral load. *Fifth International Congress on drug therapy in HIV infection; Glasgow, Scotland 22-26 October 2000*; PL3.4. AIDS 2000; 14(Suppl 4):S3.
17. **Miller V**. The value and limitations of resistance testing and how best to use it: practicalities for the physician. *Fifth International Congress on drug therapy in HIV infection; Glasgow, Scotland 22-26 October 2000*; PL4.2. AIDS 2000; 14(Suppl 4):S4.
18. Gute P, Locher L, Carlebach A, Lutz T, Staszewski S, **Miller V**. Sustained viral suppression with amprenavir plus ritonavir with abacavir/zidovudine/lamivudine in heavily pretreated patients. *Fifth International Congress on drug therapy in HIV infection; Glasgow, Scotland 22-26 October 2000*; **Abstract P40A**. AIDS 2000; 14(Suppl 4):S28.
19. Kirk O, Mocroft A, Antunes F, Pedersen C, Skinhøj P, **Miller V**, Lazzarin A, Gatell JM, Barton S, Lundgren JD for the EuroSIDA Study Group. Decreasing incidence of non-Hodgkins Lymphoma (NHL) in the era of HAART. The EuroSIDA Study. *Fifth International Congress on drug therapy in HIV infection; Glasgow, Scotland 22-26 October 2000*; **Abstract P404**. AIDS 2000; 14(Suppl 4):S133-134.
20. Yust I, Mocroft A, Turner D, Katlama C, Clotet B, Kirk O, van Lunzen J, Reiss P, Burke M, Chiesi A, and Lundgren J **for the EuroSIDA Study Group**. The effect of HAART on retinal and extraocular cytomegalovirus infection in patients with AIDS in Europe. *Fifth International Congress on drug therapy in HIV infection; Glasgow, Scotland 22-26 October 2000*; **Abstract P375**. AIDS 2000; 14(Suppl 4):S126.
21. Friis-Møller N, Kirk O, Mocroft A, Bruun JN, Johnson A, Colebunders R, Proenca R, Gonzalès-Lahoz J, d'arminio Monforte A, and Lundgren JD for the **EuroSIDA Study Group**. Admission to hospital in the HAART era: The EuroSIDA Study. *Fifth International Congress on drug therapy in HIV infection; Glasgow, Scotland 22-26 October 2000*; **Abstract P410**. AIDS 2000; 14(Suppl 4):S135.

22. Celis L, Colebunders R, Schmit JC, **Miller V**, DeMendoza C, Quinn T, Molijn H, De Smet K, Hulstzaert F. High concordance between INNO-LiPA HIV protease and DANN sequencing for genotyping of HIV protease and associated mutations. 11-13 January 2001
23. Sabin C, Phillips A, Fusco J, Youle M, Gill J, Barbour J, D'Arminio Monforte A, Dauer B, Staszewski S, Braun J, Deeks S, **Miller V**. The effect of treatment interruption in patients with virologic failure: Results from a Multi-Cohort Collaborative Study. *8<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; Chicago, USA 4-8 Feb 2001; Abstract 365.*
24. Greub G, Cozzi Lepri A, Ledergerber B, Staszewski S, Perrin L, **Miller V**, Francioli P, Furrer H, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Hirschel B, Phillips AN, Telenti A. Low-level HIV viral rebound and blips in patients receiving potent antiretroviral therapy. *8<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; Chicago, USA 4-8 Feb 2001; Abstract 522.*
25. Mocroft A, Brettle R, Kirk O, Blaxhult, Parkin JM, Antunes F, Francioli P, d'Arminio Monforte A, Phillips AN, Lundgren JD, **for the EuroSIDA Group**. Changes in cause of death across Europe. *8<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; Chicago, USA 4-8 Feb 2001; Abstract 298.*
26. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel F, Hermans P, Antunes F, Ledergerber B, Kirk O, Lundgren JD **for the EuroSIDA Group**. Virological and clinical outcome of NNRTI-containing regimens for 1932 patients in EuroSIDA. *8<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; Chicago, USA 4-8 Feb 2001; Abstract 324.*
27. **Miller V**, Schuurman R, Clavel F, Harrigan R, Hellmann N, Hertogs K, McKenna P, Race E, DiRienzo G, DeGruttola V on behalf of the EuroGuidelines Group. Comparison of HIV-1 drug susceptibility (phenotype) results reported by three major laboratories. *5<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies; Scottsdale, AZ, USA 4-8 June 2001; Abstract 169. Antiviral Ther. 2001; 6(Suppl 1): 129.*
28. Schapiro JM, De Luca A, Harrigan R, Hellmann N, McCreedy B, Pillay D, Schuurman R, Shafer RW, Vandamme A-M, **Miller V** for the Euroguidelines Group. Resistance assay interpretation systems vary widely in method and approach. *5<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies; Scottsdale, AZ, USA 4-8 June 2001; Abstract 172. Antiviral Ther. 2001; 6(Suppl 1):131.*
29. Gute P, Locher L, Carlebach A, Lutz T, **Miller V**, Staszewski S. Salvage Therapie mit Amprenavir plus Ritonavir plus Abacavir bei massiv vorbehandelten Patienten. *8. Deutscher AIDS Kongress; Berlin 4.-7. Juli 2001.*
30. Stellbrink HJ, Salzberger B, Staszewski S, Rockstroh J, Brockmeyer N, van Lunzen J, Degen O, **Miller V**, Wachsmuth JC, Reimann G, Fätkenheuer G. Eine prospektive Kohorte antiretroviral

unvorbehandelter Patienten (FITS) – Erste Zwischenauswertung. *8. Deutscher AIDS Kongress; Berlin 4.-7. Juli 2001.*

31. **Miller V**, Parrish B, Gupta S, Levi J. Quality of HIV care and reauthorization of the CARE Act. *132<sup>nd</sup> Annual Meeting of the American Public Health Association; Washington DC November 6-10, 2004.*
32. Bennett D, Rhee SY, Pillay D, **Miller V**, Sandstrom P, Schapiro J, Kuritzkes D, Shafer R. HIV-1 protease and reverse transcriptase mutations for HIV drug resistance epidemiology and surveillance. *13<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 2006; Abstract 645.*
33. Costagliola D, Cozzi-Lepri A, Assoumou KL, Cheng B, on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Initiatives for developing and comparing genotype interpretation systems: An updated analysis of validation of existing rules-based algorithm for abacavir and ddI evaluated on virological response. *Antiviral Ther.* 2006; 11:S94
34. Assoumou L, Cozzi-Lepri A, Brun-Vezinet F, DeGruttola, V, Kuritzkes, D, Phillips A, Zolopa A, **Miller V**, Costagliola D. Initiatives for developing genotype interpretation systems: derivation and validation of a didanosine interpretation system using large derivation and large validation datasets. *Antiviral Ther.* 2008; 13(Suppl 3):A102.
35. Assoumou L, Houssaini A, Costagliola D, and Flandre P, on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. *Antiviral Ther.* 2008; 13(Suppl 3):A103.
36. Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe A, **Miller V**, Bull RA, Cecherini-Silberstein F, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance. *EASL ILC 2017; Abstract Thu303.*
37. Hermerding M, Mason V, Dube K, Evans D, Goicochea P, **Miller V**. Setting the stage for meaningful community engagement and participation in HIV cure-related research: Lessons learned from the HIV prevention field. *HIV R4P 2018, Madrid.*
38. Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Glidden D, Hughes JP, Mulick C, Murray J, Roberston M, Tchelidze T, **Miller V**. HIV recent infection test-based incidence as a counterfactual for new PrEP trials. *PEC307, IAS 2021.*
39. Leus M, Crespi A, **Miller V**, Gehring A, Currie S. Immune Checkpoint Inhibitor (ICI) Treatment and Immune-related Adverse Events (IrAEs): Lessons Learned from Oncology for its

Potential Use for Chronic Hepatitis B (CHB) Patients. Poster presented at: The Liver Meeting 2024. November 15, 2024. San Diego, CA.

40. Rossi S, Walmsley M, Thorsen BT, Hatchett J, Evon DM, Reeve BB, Gomel R, Vyas MP, Safer R, Goldsmith KJ, Alastair G, Vig P, **Miller V**, Trauner M. Defining Acute Cholangitis as a Clinical Outcomes Endpoint in Adults with Primary Sclerosing Cholangitis (PSC): Results of a Multinational Patient Survey to Develop a Patient-Reported Outcomes Measure (PROM). Poster presented at: AASLD. November 18, 2024. San Diego, CA.

### Invited Presentations

- 1997 4. Deutscher Kongress für Infektions- und Tropenmedizin, KAAD Symposium: Phänotypische und genotypische Resistenz: Wirksame Instrumente zur Therapiesteuerung? (**Plenary**)
- 1998 Kober Center, Chelsea & Westminster Hospital: Clinical Implications of HIV-Drug Resistance (**Seminar**)
- 1998 I. Norddeutscher Workshop: Interdisziplinäre Infektiologie: Bedeutung der Resistenztestung für die Therapieentscheidungen des klinischen Alltags (**Plenary**)
- 1998 Royal College of Physicians: Clinical implications of HIV-1 drug resistance. Unmasking the Thief: HIV-drug Resistance (**Plenary**)
- 1998 International Workshop on Salvage Therapy for HIV Infection: Frequency and predictors of triple therapy failure (**Research Presentation**)
- 1999 FDA Antiviral Committee Advisory Meeting on Clinical Significance of HIV Drug Resistance (**Invited Presenter**)
- 1999 University of Colorado Health Sciences Center HIV Opinion Leader Investigators Meeting: Combination Antiretroviral Therapy: Correlates of Success or Failure (**Plenary**)
- 2000 Fifth International Congress on Drug Therapy in HIV Infection: The value and limitations of resistance testing and how best to use it: Practicalities for the physician (**Plenary**)
- 2000 The British HIV Association Conference: Resistance testing: where are we now, where are we going? (**Plenary**)
- 2000 Imperial College Fourth Annual Resistance Meeting: HIV Drug Resistance: What have we learned from cohort studies? (**Plenary**)
- 2000 39<sup>th</sup> ICAAD: Antiretroviral Treatment Interruptions (**State-of-the-Art**)
- 2000 6<sup>th</sup> Australian Seminar, Virology in Perspective: Management of HIV treatment failure (**Plenary**)
- 2000 XI. Austrian AIDS Congress: To interrupt or not to interrupt, is this the (salvage) question? (**Plenary**)
- 2000 8th ECCATH: Guidelines for the clinical use of HIV drug resistance testing (**Plenary**)
- 2001 Workshop on Clinical Pharmacology of Antiretroviral Therapy: Resistance Testing (**Plenary**)

- 2001 National Institute for Infectious Diseases (Italy) Workshop on Emerging Issues of HIV Infection: Management of patients failing HAART (**Plenary**)
- 2001 Gladstone Institute of Virology and Immunology: Immunologic, virologic and clinical consequences of antiviral treatment interruptions (**Seminar**)
- 2002 International HIV Workshop on Management of Treatment-Experienced Patients: Determinants of Treatment Failure: Resistance (**Plenary**)
- 2002 12<sup>th</sup> International Symposium on HIV and Emerging Infectious Diseases: HIV-1 Drug Resistance: Basic mechanisms and clinical significance (**Plenary**)
- 2002 10<sup>th</sup> International Congress on Infectious Diseases: Planned Treatment Interruptions (**Plenary**)
- 2003 Department of Infectious Diseases, University of Colorado: Definitions of Treatment Failure (**Grand Rounds Seminar**)
- 2003 British HIV Association, BHIVA **Foundation Lecture**
- 2004 7th International Congress on Drug Therapy in HIV Infection: Salvage Therapy: Feedback of the Forum Workshop (**Plenary**)
- 2004 6<sup>th</sup> Annual Alberta Infectious Disease Conference (**Keynote**)
- 2004 Summit on HIV Spring 2004 (**Keynote**)
- 2004 8<sup>th</sup> International HIV Observational Database Workshop: HIV- Drug Resistance: Definitions and Analyses (**Plenary**)
- 2005 Pennsylvania/Mid Atlantic AIDS Education and Training Center Annual Spring Conference: Structured Treatment Interruptions: Role in Research vs. Clinical Practice (**Workshop Chair and Speaker**)
- 2005 German/Austrian HIV Conference (**Symposium Talk**)
- 2005 CDC Consultation on Infant HIV Diagnosis (**Invited Presenter**)
- 2006 8<sup>TH</sup> International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (**Report**)
- 2007 German/Austrian HIV Conference (**Plenary**)
- 2007 IOM Committee on Methodological Challenges in HIV Prevention Trials (**Invited Talk**)
- 2007 INTEREST Workshop, Kampala Uganda (**Invited Talk**)
- 2007 World Bank Session at INTEREST Workshop, Kampala, Uganda (**Plenary**)
- 2007 4<sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney, Australia (**Plenary**)
- 2008 2<sup>nd</sup> Interest Workshop, Dakar, Senegal (**Invited Talk**)
- 2009 UNO Global Health Conference, Omaha, Nebraska (**Keynote**)
- 2010 UMDNJ Medical Grand Rounds (**World AIDS Day Lecture**)
- 2012 IAPAC-BHIVA TasP Summit, London UK; PreP- Safety Considerations (**Plenary**)
- 2013 IAPAC-BHIVA TasP Summit, London UK; PrEP – Regulatory Considerations (**Plenary**)
- 2014 AASLD Emerging Trends Conference on Antifibrotic Drug Trials: Strategies and Endpoints, Chicago, USA; Accelerating the Path to Antifibrotic Drug Development: Lessons from HIV and HCV (**Invited Talk**)
- 2014 Rare Disease Collaboration Summit, Philadelphia, USA; Case Study: Collaborating with Patient Groups to Advance Knowledge of Disease Natural History (**Invited Talk**)

- 2014 PhRMA Global IP Summit; Medicines and the Role of Innovation on Progress on HIV/AIDS (**Panelist**)
- 2014 PRIMR Advancing Ethical Research Conference; Panel VIII: Issues related to the HIV/AIDS epidemic and populations affected (**Invited talk and Panelist**)
- 2015 CUNY Public Health Grand Rounds: Drug Development, Implementation and Access to Treatment: The Hepatitis C Case Study (**Keynote**)
- 2015 Gothia Forum, Gothenburg: Accelerating Drug Development through Collaboration (**Invited Talk**)
- 2015 ICAAC, San Diego: What's New on Antiretroviral Therapy (**Session Convener and Invited Speaker**)
- 2015 STOPNASH, Washington DC: Opportunities for Collaboration (**Invited Speaker**)
- 2016 AASLD/FDA Conference on Trial Design and Endpoints for Clinical Trials in Adults and Children with Primary Sclerosing Cholangitis (**Invited Speaker**)
- 2016 2<sup>nd</sup> Paris NASH Symposium (**Invited Special Lecture**)
- 2016 Women in High Places: leading the Global Challenge of Hepatitis and Liver Cancer Control (**Invited Speaker**)
- 2016 Lausanne III, The Road to 2025: Delivering the Next Generation Alzheimer's Treatments (**Invited Speaker**)
- 2016 Women's Research Initiative on HIV/AIDS (**Invited Speaker**)
- 2018 COFEPRIS Semana Internacional de Ciencia Regulatoria (**Invited Speaker**)
- 2018 Singapore Hepatitis Conference/Science of HBV Cure (**Invited Speaker**)
- 2018 USAID Symposium. Establishing the Scientific Framework for PrEP Trials. Washinton, DC (**Invited Speaker**)
- 2018 University of Puerto Rico. Drug Development, Regulatory Approval and Public Health. San Juan, PR. (**Plenary Talk**)
- 2018 National Medical Products Administration. The Forum for Collaborative Research. Special presentation to leadership group. Beijing, China
- 2018 Stanford Medicine Symposium on HDV and HBV. The Path to HBV Cure. Stanford CA (**Plenary Talk**)
- 2018 AARR (Alzheimer's Association Research Roundtable). Lessons Learned from Combination Therapies in Other Disease Areas. Washington, DC (**Plenary Presentation**)
- 2019 Convencion Nacional de Responsables Sanitarios de la Industria Quimico Farmaceutica. Regulatory Science in Action. Mexico City, Mexico
- 2019 Encuentro Internacional Regulatorio de Medicamentos Y Dispositivos Medicos. The Forum for Collaborative Research: A Model for Innovation in Regulatory Science Practice, Education, & Training. Havana, Cuba
- 2019 EF-CLiF. Some Thoughts on Drug Development for Acute on Chronic Liver Failure. Venice, Italy (**Plenary Speaker**)
- 2019 Singapore Hepatitis Conference/Science of HBV Cure (**Invited Speaker**)
- 2020 European Conference Rare Diseases (EURORDIS) (**Invited Speaker**)
- 2020 Colegio Nacional de Quimicos Farmaceuticos Biologos Mexico (**Invited Speaker**)
- 2020 NextGenDx. Multi-Stakeholder Collaboration for NAFLD Detection and Intervention. (Virtual) (**Keynote Speaker**)

- 2020 PSC Partners Webinar. Participating in Clinical Trials (Virtual) **(Keynote Speaker)**
- 2021 6<sup>th</sup> International Meetings Regulatory Affairs (AMEPRES) **(Invited Speaker)**
- 2021 First HIV Prevention Symposium - Brazil. Challenges in the Design of PrEP Trials (Virtual) **(Invited Speaker)**
- 2021 IAS Symposium. What we learned from AMPT trials. **(Introductory remarks and Moderator)**
- 2021 HepDART. Liver and HBV Forum Updates. Los Cabos, Mexico **(Plenary Speaker)**
- 2022 CZI (Chan Zuckerberg Initiative) Rare as One. External Controls in FDA Regulatory Decision Making. Virtual **(Keynote Speaker)**
- 2022 European Medicines Agency. The Jordi Llinares Lecture: The Liver Forum: How Collaborative Partnerships Facilitate Drug Development. **(Keynote Presentation)**
- 2022 CZI Rare as One. Designing Trials for Rare Diseases: External Controls and Other Considerations. Virtual **(Keynote Speaker)**
- 2022 NOhep Medical Visionaries. The Path to HBV Cure: Regulatory Riddles & Research Partnerships. London. **(Invited Speaker)**
- 2022 VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health Inaugural Academic Symposium. “The Liver Forum: Collaborative Partnerships Facilitate Drug Development”. Richmond, VA **(Invited Plenary Talk)**
- 2022 24<sup>th</sup> International AIDS Conference **(Invited Speaker)**
- 2023 Global PBC Study Group 10<sup>th</sup> Anniversary. “Working Together: The Route to Success”. Rotterdam, Netherlands **(Invited Speaker)**
- 2023 HepDART. “Challenges in Drug Development for Steatotic Liver Disease. Advances through Collaboration”. Los Cabos, Mexico **(Plenary Speaker)**.
- 2023 BMGF Grand Challenges in Dakar, Senegal **(Invited Speaker)**
- 2023 FIORD (Forum on the Integration of Observational and Randomized Data). “Perspective and Activities at the Forum for Collaborative Research”. Washington, DC **(Invited Speaker)**
- 2024 Health Care Conference Taipei (UCB Public Health, JP Morgan, Stanford and Taipei Regent). Taipei, Taiwan. **(Closing Panel Presenter)**.
- 2024 ECM Conference, Copenhagen **(Invited Speaker)**
- 2024 2<sup>nd</sup> Multi-Stakeholders Meeting on Clinical Trials for Inherited Retinal Diseases. Dublin, Ireland **(Invited Speaker and Panelist)**
- 2024 Clinical Trial Design Academy. External Controls in Clinical Trials. Virtual. **(Invited Speaker)**
- 2024 COLDA (Conference on Liver Diseases in Africa). Supporting Africa-Led Implementation and Clinical Research in Viral Hepatitis. Cairo, Egypt **(Invited Session Organizer and Speaker)**

## TEACHING AND MENTORING (Berkeley)

### Teaching

- 2012 – present PH236: US Food and Drug Administration, Drug Development and Public Health

2017 – present PHW236A: Regulatory Science, Drug Development and Global Health  
2022 – present PH290 Seminar: Diagnostics in Infectious Diseases: Development and Regulatory Challenges (Instructor of Record; co-taught with John Sninsky and Pete J. Dailey)

## Mentoring (Berkeley)

### MPH, JPM and OOMPH Program

2011 Katharine Burmaster JMP: Regulatory path for next generation sequencing technologies

2012 Nivedha Panneer: Advances in diagnostic technologies and algorithms for HIV and HCV testing. **Publication: Panneer et al, CID 2014**

2013 Courtney Hutchison: Telling the HCV DrAG story – documenting its impact on progress in HCV drug development. **Publication: Hutchison et al, CPT 2014**

2013 Devon Okasako-Schmucker: Overcoming Bay Area Health Disparities: Databases and other sources of information available to assess and monitor program impact

2013 Roxanne Clement-Rorick: Overcoming Bay Area Health Disparities: Connecting and strengthening community based research across the Bay Area

2014 Micha Zheng: Safer conception for HIV serodiscordant couples

2015 Jonathan Liu: Stakeholder perspectives on HBV drug development. **Publication: Liu et al, JVE, 2017**

2016 Megan McIntosh: Stakeholder perspectives on CMV drug development. **Publication: McIntosh et al, JVE 206**

2017 Melissa Hermerding: Good Participatory Practice: from HIV to HBV Cure. **Publication: Hermerding et al, oral presentation at R4P 2018 with full conference scholarship.**

2019 Ryan Taylor Anderson: Perspectives on combination treatment for HBV finite treatment. **Publications: Anderson et al, Gastroenterology 2019; Anderson et al, Clin Gastroenterol Hep 2021**

2019 Angela Monahan: Role of immune diagnostics in CMV

2020 Joseph Lau: HIV recency assay to estimate cross-sectional HIV incidence. **Publications: Kin-On Lau et al, JVE 2022**

2020 Daniel Mota: Statistical innovation in rare disease drug development

2020 Tinkhani Mbchila: HIV prevention clinical trial design. **Publication: Mbichila et al, JVE 2021**

2020 Frederique Sauve: Predictive value of CMV immune diagnostics. **Publications: in preparation**

2020 Bonnie Xu: Emergency Use Authorization in current and recent pandemics

2021 Emily Gainor: Stakeholder perspectives for HHV6 drug development in transplantation setting. **Publication: in preparation**

2021 Kelsey MacCuish: Review of NASH trials

- 2021 Nick Murdock: HIV prevention trial designs
- 2022 Mitchell Leus: Challenges in HIV prevention trials
- 2022 Aliya Mahmoud: HBV adult vaccination programs
- 2022 Nayri Alajaji: Increasing access to long-acting HIV treatments. **Publication: Murdock et al, OFID 2024**
- 2023 Sarah Alhakimi: regulatory considerations for multi-purpose prevention technologies. **Publication: Submitted**
- 2023 Mayland Treat: Elimination of HBV in US. **Publication: Leus et al, JVE 2024**
- 2024 Roma Ranade: Prevention and treatment of measles in transplantation setting.

**Graduate and Senior Fellows**

- 2010 Nyasha Bakare MD MPH – JHU Prevention Medicine Rotation. Pharmacovigilance of ARVS in treatment and prevention for resource limited settings. **Publication: Bakare et al, PLOS 2011**
- 2012 Erik Lontok PhD – Post-doctoral fellow from UCSF – HIV and HCV diagnostics and algorithms. **Publications: Lontok et al, CID 2013**

**Post-Doctoral Scholar**

- 2023- Robin Schaefer MPH PhD. Advancing global regulatory science for HIV prevention and treatment. **Publications: Murdock et al, OFID 2024; 3 submitted manuscripts under review**

**SERVICE**

**Committee Assignments**

**The George Washington University**

- 2004-2005 Search Committee for Department of Global Health Chair Chair
- 2005-2010 GWU HIV/AIDS Institute CME series Director
- 2005-2010 The GWU HIV/AIDS Institute Executive Committee Founding Member
- 2007-2008 Search Committee for Track Director, Public Health Communications & Marketing Chair

**UC Berkeley**

- 2020-2023 IDV MPH Admissions Committee Chair
- 2022 Departmental Ad Hoc Committee for Promotion Member
- 2023- Online Education Faculty Steering Committee Member

**National and International**

- 1999 European Medicines Evaluation Agency Expert Consultant

1999-2001	EuroGuidelines Group Expert Panel on the Implications of HIV Drug Resistance and Resistance Testing Steering Committee	Chair
2000-2004	Joint DoD/NIAID Tri-Services AIDS Clinical Consortium	External Advisor
2000-2010	WHO/IAS Global Monitoring of the Emergence of Antiretroviral Resistance	Expert Advisor
2001-2010	Campbell Foundation Peer Review Board	Member
2001-2010	Swiss National Science Foundation	Reviewer
2003	CDC Review Panel for Topical Microbicides in Heterosexual Women and Men	Peer Reviewer
2004	NIH Special Emphasis Panel for Microbicide/HIV Vaccine Acceptability and Enrolling Women and Minority in Clinical Trials	Reviewer
2004	BMGF Grand Challenges in Global Health, Panel 5	Reviewer
2004-2006	Global Fund to Fight AIDS, Tuberculosis and Malaria Technical Review Panel Support Group	Member
2005	FDA Antiviral Drugs Advisory Committee	Voting Member
2005	NIH/OAR Key Strategies Planning for FY07 Committee	Member
2005-2010	CME committee for the GWU and Greater Washington DC	Chair
2006	NIH/OAR Key Strategies Planning FY08 Committee	Member
2006	NIH/DAIDS Special Emphasis Panel for Clinical Trial Units	Reviewer
2006	FDA Office of Women's Health Intramural Scientific Research Program	Reviewer
2007	NIH/DAIDS Review Panel for HIV Prevention Trials	Reviewer
2007	IOM report <i>Methodological Challenges in Biomedical HIV Prevention Trials</i>	Reviewer
2007-2010	DSMB: THESIS Study, University of Modena	Member
2008-2015	DSMB: ISS T-002 and T-003 Vaccine Trials (Istituto Superiore de Sanita, Rome)	Member
2008-2012	Scientific Advisory Board, CONRAD Microbicide Development Program	Member
2009-2014	Study Monitoring Committee MTN015	Member
2010-2013	DSMB: NEAT001/ANRS143 trial	Member
2011	NIH/PEPFAR Collaboration Implementation Science and Impact Evaluation	Reviewer
2013	NIH Network Re-Competition IMPAACT	Reviewer
2014	ICMC: RIVER Study, Imperial College, London	Member
2015-2018	Canadian HIV Trials Network External Advisory Committee	Member
2022	Science Foundation Ireland: Frontiers for the Futures Program in Regulatory Science	Reviewer
2024-2025	EDCTP/PENTA UNIVERSAL Studies Independent Committee	Member

## Editorial Boards & Peer-Reviewer

2000-2003	AIDS Editorial Board	Member
2024-	Journal of Public Health (JPHIA) in Africa Editorial Board	Member
2014-	Journal of Virus Eradication Editorial Committee	Member
2001-	Ad hoc reviewer for several journals	

## Conference Leadership (selected)

1999-2001	European Symposium for Clinical Implications of HIV Drug Resistance	Conference Co-Chair
2000-2014	International Workshop on HIV Observational Databases	Steering Committee
2004	6 <sup>th</sup> International Workshop on Adverse Drug Reactions and Lipodystrophy	Conference Co-Chair
2004	NIH/NIAID/DAIDS Cohorts Meeting	Steering Committee
2004	Third Annual John M. Lloyd AIDS Project: Racial Disparity	Steering Committee
2004-2012	International Congress on Drug Therapy HIV Infection	Scientific Committee
2007	Statistical and Epidemiologic Methods in HIV Research (in collaboration with NIH/NIAID/DAIDS)	Organizing Committee
2022-	MOSAIC Think Tank	Conference Co-Chair
2014-	PARIS NASH	Organizing Committee and Presenter
2023	International AIDS Society 12 <sup>th</sup> Conference on HIV Science	Session Moderator

## MEMBERSHIPS

2001-	International AIDS Society (IAS)
2004-	Infectious Disease Society of America (IDSA)
2004-	HIV Medicine Association (HIVMA)
2012-	European Association for the Study of the Liver (EASL)
2014-	American Association for the Study of Liver Disease (AASLD)
2024-	Association for Research in Vision and Ophthalmology (ARVO)
2024-	European Society for Retinal Specialists (EURETINA)
2024-	Regulatory Affairs Professional Society (RAPS)